Business ❯ Finance ❯ Investments ❯ Stock Market

Pharmaceutical Stocks

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

The once-daily peptide offers biologic-like efficacy without injections.

HSBC Cuts Eli Lilly to Reduce, Lowers Target to $850 on GLP-1 Reset

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

ImmunityBio Shares Rise on ANKTIVA Surge, Saudi Approval for Lung Cancer

Novo Nordisk Sues Hims & Hers to Halt Compounded Wegovy Copycats

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Hims Launches $49 Compounded Wegovy-Style Pill as Novo Vows Legal Action

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

Merck Ends Revolution Medicines Takeover Talks After Valuation Standoff

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

Bristol Myers Gains Analyst Support as 2026 Catalysts Offset Patent-Cliff Worries

Merck Lifts Mid-2030s Revenue Goal to $70 Billion From Emerging Businesses

ImmunityBio Rallies as Anktiva Sales Surge 700% and Registrational Trial Passes 85% Enrollment

TG Therapeutics Lifts 2026 Outlook After Strong Briumvi Year, Shares Jump

Tempus AI Reports 83% 2025 Revenue Surge as TCV Tops $1.1 Billion, Adds Major Cancer-Care Partnerships

Amazon Pharmacy Adds FDA-Approved Wegovy Pill With $25 Copays and Nationwide Delivery

Eli Lilly Shifts to Access-First Strategy on GLP-1 Strength

Novo Nordisk Presses India Expansion and Higher-Dose Push as Analyst Views Diverge

HSBC Upgrades AbbVie to Buy, Lifts Target to $265 as Skyrizi and Rinvoq Drive Growth

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses